Aristotle University Of Thessaloniki (AUTH)
Identification and functional verification of new molecular targets of blood – cerebrospinal fluid and exosomes from patients with neurodegenerative diseases
Abstract
dc:descriptionNeuronal degeneration and dysfunction are hallmark characteristics of neurodegenerative diseases (NDs). Currently, a significant challenge for researchers and clinicians is the development of reliable diagnostic tools that enable early diagnosis of NDs preferably in the presymptomatic stage. Despite decades of research and the approval of a small number of drugs by the Food and Drug Administration (FDA), halting the cognitive decline associated with neurodegeneration, continues to be a formidable challenge. Currently, the diagnosis of the majority of NDs relies on clinical examination and imaging techniques. Although these disorders arise from distinct pathophysiological mechanisms, they share overlapping fluid- and blood-based biomarkers, contributing to their diagnosis and characterization. Towards this direction, the first scope of the current dissertation thesis is the quantitative determination of selected protein biomarkers in cerebrospinal fluid (CSF) and blood (plasma/serum) to support the differential diagnosis of various NDs. Initially, the study started with the measurement of single plex trials of urokinase plasminogen activator surface receptor (uPAR) in a limited cohort of well characterized sporadic Creutzfeldt-Jakob disease (sCJD) patients, TAU protein, α-synuclein (α-syn) and YKL-40 (Chitinase 3-like 1) in a broad cohort of patients with synucleinopathies (Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple system atrophy (MSA)). The resulting biomarker concentrations lacked in sensitivity and specificity, not showing distinct cut-off values, highlighting the need for increased accuracy immunoassay-based platforms, providing a broader detection range for a more effective disease diagnosis and discrimination. Thus, a multiplex SIMOA panel of four biomarkers (glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), TAU, and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)), in two different clinical cohorts, was facilitated. Receiver operating characteristic (ROC) curve and area under the curve (AUC) analysis assessed the diagnostic accuracy of the tested biomarkers in CSF and blood of the patient cohorts. Regarding Alzheimer’s disease (AD) and Frontotemporal dementia (FTD) patients, the biomarker with the best diagnostic performance was CSF UCH-L1. The optimal cut-off values were identified at >1260 pg/mL for AD and >1052 pg/mL for FTD, supporting the utility of UCH-L1 as a promising biomarker for the differential diagnosis of these NDs. CSF NfL showed a good diagnostic accuracy distinguishing AD and FTD patients from Controls, with cut-off values at >688.8 pg/mL and >463.9 pg/mL, respectively. CSF TAU was the biomarker with the second-best performance after CSF UCH-L1 in discriminating AD patients from Controls, with calculated cut-off value >137.0 pg/mL, while showed a good diagnostic accuracy in the differentiation of AD from FTD patients. Also, good performance showed regarding FTD and Controls, with a cut-off value >111.3 pg/mL. Finally, CSF GFAP marked a fair diagnostic accuracy in the discrimination of AD patients from Control group, with cut-off value >5942 pg/mL. In the same pattern plasma and CSF GFAP indicated fair diagnostic performance in the differentiation of AD from FTD patients.In Multiple sclerosis (MS) and Clinically isolated syndrome (CIS), serum and CSF NfL illustrated a fair diagnostic accuracy in the discrimination of MS from CIS and Controls, with cut-off values >5.909 pg/mL and >453.4 pg/mL, respectively. Serum TAU was the biomarker with the best performance in distinguishing CIS from Controls, forming a cut-off value >0.5950 pg/mL, while in CSF was <75.26 pg/mL. Similar to these thresholds, it was also serum TAU diagnostic performance for MS patients, with cut-off values at >0.5823 pg/mL (in serum) and <76.47 pg/mL (in CSF). Lastly, serum GFAP showed a fair discriminating accuracy between MS and Controls with a cut-off value >48.08 pg/mL. To conclude, our results gave a new perspective and insights regarding UCH-L1 and GFAP in AD - FTD cohort and NfL and TAU in MS group, showing their potential implication in neuronal damage, protein degradation and disease progression. The second goal of the study is the investigation of the role of neuronal exosomes in the pathogenesis and spread of NDs (with emphasis on Prion disease). For this purpose, a pathogenic RML (Rocky Mountain Laboratories) mouse model was facilitated, giving us access to brain-derived exosome-enriched extracellular vesicles (ExE-EVs). Our study, showed that neuronal exosomes from healthy and Prion pathogenic mice, at early and late stages of the disease, share the same double-membrane, cup-shaped morphology, 50-200 nm ranging size and quantity (particles/mL). Proteomic analysis revealed 4337 proteins of which 1272 proteins found differentially regulated between Prion and Control groups. These alterations were mostly associated with mitochondrial function and endoplasmic reticulum (ER) membrane regulations. Prion pathology was one of the top pathways overrepresented in our database, consisting of 14 proteins showing differences in their abundance levels between Control and disease stage. More specifically, the main protein of our interest, Prion protein (PrP), showed 16-fold increase in the late stage of the Prion disease in comparison with the healthy mice. Together, this thesis offers a comprehensive overview of proteomic biomarkers of CSF, blood and exosomal material, in a variety of NDs. This thesis’ findings could contribute significantly to the field of biomarkers’ discovery, enhancing our understanding of their pathophysiology and their cut-off levels in scope of early and accurate diagnosis and therapeutic interventions.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatziefstathiou, Athanasia
- Χατζηευσταθίου, Αθανασία
Subjects
dc:subject × 26- Νευροεκφυλιστικές ασθένειες
- Διαφορική διάγνωση
- Εγκεφαλονωτιαίο υγρό
- Αίμα
- Βιοδείκτες
- Πλατφόρμα SIMOA
- RML μοντέλο μυός
- Εξωσώματα
- Πρωτεομική
- Neurodegenerative diseases
- Differential diagnosis
- Cerebrospinal fluid
- Blood
- Biomarkers
- SIMOA platform
- RML mouse model
- Exosomes
- Proteomics
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία, άλλοι τομείς
- Βιοχημεία και Μοριακή βιολογία
- Biological Sciences
- Natural Sciences
- Biology, miscellaneous
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61089